Linked Life Data

17647121

Source:http://linkedlifedata.com/resource/pubmed/id/17647121

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2007-7-24
pubmed:abstractText
CLINICAL CASE: A 71-year-old man presented with pseudophakic cystoid macular edema (PCME) and a visual acuity (VA) of 0.1. He had been treated with 2 intra-vitreal injections of triamcinolone acetonide (4 mg) 16 months previously. One week after the intra-vitreal injection of bevacizumab (1.25 mg), VA improved to 0.33, and the OCT demonstrated decreased macular thickness. Two months after the injection, no ocular complications were observed, VA was 0.5 and the OCT showed a significant reduction in the retinal thickness. CONCLUSION: Intra-vitreal injection of bevacizumab may be an additional tool for the treatment of therapy-resistant PCME.
pubmed:language
spa
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0365-6691
pubmed:author
pubmed:issnType
Print
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
447-50
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Intravitreal injection of bevacizumab for pseudophakic cystoid macular edema resistant to steroids].
pubmed:affiliation
Consorcio Hospital General Universitario de Valencia, Valencia, España.
pubmed:publicationType
Journal Article, English Abstract, Case Reports